{"id":"er-niacin","safety":{"commonSideEffects":[{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperuricemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Niacin works through multiple pathways: it inhibits hepatic diacylglycerol acyltransferase-2 (DGAT2) and reduces free fatty acid mobilization from adipose tissue, thereby decreasing hepatic triglyceride and VLDL production. It also increases HDL cholesterol through upregulation of apolipoprotein A-I and reduces LDL cholesterol. The extended-release formulation improves tolerability by reducing the flushing side effect associated with immediate-release niacin.","oneSentence":"ER-niacin is an extended-release formulation of niacin (vitamin B3) that raises HDL cholesterol and lowers triglycerides and LDL cholesterol.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:19.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia; elevated triglycerides and low HDL cholesterol in patients at risk for cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT02322203","phase":"NA","title":"Effects of Niacin Therapy on Lipoprotein Composition and Function","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-03-25","conditions":"Cardiovascular Disease","enrollment":22},{"nctId":"NCT02702492","phase":"PHASE1","title":"PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2016-06-08","conditions":"Solid Tumors, NHL","enrollment":60},{"nctId":"NCT01274559","phase":"PHASE3","title":"Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1173},{"nctId":"NCT00271817","phase":"PHASE3","title":"To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":1220},{"nctId":"NCT04281420","phase":"PHASE1","title":"A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Antengene Therapeutics Limited","startDate":"2020-04-13","conditions":"Solid Tumor, Non-Hodgkin's Lymphoma","enrollment":20},{"nctId":"NCT03563170","phase":"PHASE1, PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent","enrollment":""},{"nctId":"NCT00508989","phase":"PHASE2","title":"Niacin to Improve Blood Flow in People With Sickle Cell Disease","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2007-07-24","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT02624700","phase":"PHASE2","title":"2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2016-01-28","conditions":"Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":13},{"nctId":"NCT01984073","phase":"PHASE1","title":"Effects of Niacin On Fatty Acid Trapping","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-12","conditions":"Dyslipidemia","enrollment":26},{"nctId":"NCT00769132","phase":"PHASE1","title":"A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08-03","conditions":"Hypercholesterolemia","enrollment":26},{"nctId":"NCT01683656","phase":"PHASE4","title":"ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART","status":"TERMINATED","sponsor":"Calmy Alexandra","startDate":"2012-08","conditions":"HIV, Atherosclerosis","enrollment":4},{"nctId":"NCT00479882","phase":"PHASE3","title":"MK-0524B Lipid Study (MK-0524B-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":2414},{"nctId":"NCT01335997","phase":"PHASE3","title":"Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-01","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1139},{"nctId":"NCT00289900","phase":"PHASE3","title":"Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01-24","conditions":"Mixed Hyperlipidemia","enrollment":2340},{"nctId":"NCT01294683","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02-04","conditions":"Primary Hypercholesterolemia, Dyslipidemia","enrollment":977},{"nctId":"NCT02018965","phase":"PHASE2","title":"Niacin on Immune Activation : a Proof-of-concept Study","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2011-11","conditions":"HIV","enrollment":16},{"nctId":"NCT00359281","phase":"PHASE2","title":"Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Healthy","enrollment":125},{"nctId":"NCT03370848","phase":"PHASE4","title":"Effects of Psyllium on Niacin Tolerability","status":"COMPLETED","sponsor":"VA Greater Los Angeles Healthcare System","startDate":"2009-03","conditions":"Flushing, Hyperlipidemias, Dyslipidemias","enrollment":26},{"nctId":"NCT00300365","phase":"PHASE2","title":"Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2005-11","conditions":"Metabolic Syndrome","enrollment":38},{"nctId":"NCT00376584","phase":"PHASE3","title":"Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":"Hypercholesteremia, Hyperlipidemia","enrollment":825},{"nctId":"NCT01052311","phase":"PHASE4","title":"The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2010-07","conditions":"Coronary Artery Disease, Dyslipidemia","enrollment":8},{"nctId":"NCT01194869","phase":"PHASE2","title":"Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer","status":"TERMINATED","sponsor":"Emory University","startDate":"2010-06","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT00728910","phase":"PHASE2","title":"Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-06","conditions":"Dyslipidemia","enrollment":25},{"nctId":"NCT00573755","phase":"PHASE2","title":"Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2007-12","conditions":"Breast Cancer","enrollment":4},{"nctId":"NCT01426438","phase":"PHASE2","title":"Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11","conditions":"HIV-1 Infection","enrollment":99},{"nctId":"NCT01583647","phase":"PHASE1","title":"A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06","conditions":"Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia","enrollment":10},{"nctId":"NCT01012219","phase":"PHASE1","title":"A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":36},{"nctId":"NCT00485758","phase":"PHASE3","title":"Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Diabetes Mellitus Type 2","enrollment":796},{"nctId":"NCT00804843","phase":"PHASE2","title":"Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Carotid Atherosclerosis","enrollment":100},{"nctId":"NCT00618995","phase":"PHASE1","title":"A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08","conditions":"Type 2 Diabetes Mellitus","enrollment":26},{"nctId":"NCT00269204","phase":"PHASE3","title":"Lipid Efficacy/Tolerability Study (0524A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12","conditions":"Primary Hypercholesterolaemia, Mixed Hyperlipidaemia","enrollment":1620},{"nctId":"NCT00943124","phase":"PHASE1","title":"MK0524B Bioequivalence Study (0524B-070)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Dyslipidemia","enrollment":220},{"nctId":"NCT00944645","phase":"PHASE1","title":"MK0524A Bioequivalence Study (0524A-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10","conditions":"Dyslipidemia","enrollment":188},{"nctId":"NCT00664287","phase":"PHASE3","title":"Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09","conditions":"Dyslipidemia","enrollment":""},{"nctId":"NCT00479388","phase":"PHASE3","title":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1216},{"nctId":"NCT00961636","phase":"PHASE3","title":"A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10","conditions":"Dyslipidemia","enrollment":1152},{"nctId":"NCT00461630","phase":"PHASE3","title":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-01","conditions":"Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus","enrollment":25673},{"nctId":"NCT01126073","phase":"PHASE4","title":"Niacin/Laropiprant and Endothelial Function","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2010-09","conditions":"Coronary Heart Disease","enrollment":60},{"nctId":"NCT01010516","phase":"PHASE4","title":"Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia","status":"UNKNOWN","sponsor":"University of Ioannina","startDate":"2009-10","conditions":"Dyslipidemia","enrollment":120},{"nctId":"NCT00465088","phase":"PHASE3","title":"An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-04","conditions":"Hyperlipidemia, Mixed Dyslipidemia","enrollment":199},{"nctId":"NCT00071266","phase":"PHASE3","title":"The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC","status":"COMPLETED","sponsor":"Kos Pharmaceuticals","startDate":"2003-10","conditions":"Intermittent Claudication, Peripheral Vascular Disease","enrollment":870},{"nctId":"NCT00062556","phase":"PHASE3","title":"Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication","status":"COMPLETED","sponsor":"Kos Pharmaceuticals","startDate":"2003-01","conditions":"Intermittent Claudication, Peripheral Vascular Disease","enrollment":366},{"nctId":"NCT00080275","phase":"PHASE3","title":"Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)","status":"COMPLETED","sponsor":"Kos Pharmaceuticals","startDate":"2004-03","conditions":"Hypercholesterolemia","enrollment":600},{"nctId":"NCT00082251","phase":"PHASE3","title":"Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST","status":"COMPLETED","sponsor":"Kos Pharmaceuticals","startDate":"","conditions":"Hypercholesterolemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"BLOOD ALKALINE PHOSPHATASE INCREASED"},{"count":1,"reaction":"DEHYDRATION"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"LIVER FUNCTION TEST INCREASED"},{"count":1,"reaction":"PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED"},{"count":1,"reaction":"SINUS DISORDER"},{"count":1,"reaction":"SYNCOPE"}],"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ER-niacin","genericName":"ER-niacin","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ER-niacin is an extended-release formulation of niacin (vitamin B3) that raises HDL cholesterol and lowers triglycerides and LDL cholesterol. Used for Dyslipidemia; elevated triglycerides and low HDL cholesterol in patients at risk for cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}